Cynapsus Therapeutics’ (TSX-V:CTH) APL-130277 for Parkinson’s disease was recognized as one of the Top Ten Neurology Projects to Watch in 2012 by a joint selection committee, including Dr. Harry Tracy, a noted authority on pharmacological interventions for diseases of the brain and editor of the highly respected biotechnology publication NeuroPerspective, as well as with Elsevier Business Intelligence, the publishers of In Vivo, Startup and The Pink Sheet.
Cynapsus also has been invited to present at Elsevier’s Therapeutic Area Partnerships Meeting on Nov. 28-30 in Boston.
Two famous Parkinson’s patients
“We are humbled to be recognized from among several hundred worthy neuroscience projects, worldwide,” CEO Anthony Giovinazzo said in a statement. “This is a significant honor and further independent validation of the potential of APL-130277.”
APL-130277 is a sublingual thin film strip formulation of apomorphine, which is now administered as an injection or infusion to Parkinson’s patients experiencing daily “OFF” or motor fluctuation episodes. As a new means of delivering an approved drug, APL-130277 is expected to follow a bioequivalence regulatory and clinical path, culminating in a New Drug Approval application in 2015.
Mr. Giovinazzo pointed out that the number of Parkinson’s patients worldwide could potentially increase two-to-three fold over the next eight-to-10 years. “This significant potential unmet medical need, coupled with a short and lower risk clinical pathway, would be of interest to many in global and specialty pharma, especially given that our pending patent estate, when approved and granted, would provide protection to 2031 at a minimum,” he added.
